Roche is preparing regulatory filings for its crovalimab antibody for rare disease paroxysmal nocturnal haemoglobinuria (PNH), after a phase 3 trial showed the drug was as effective as AstraZeneca ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...